Skip to main content
NANOVIRICIDES, INC. logo

NANOVIRICIDES, INC. — Investor Relations & Filings

Ticker · NNVC ISIN · US6300873022 LEI · 5493003CK9Y2H0OORR73 US Professional, scientific and technical activities
Open in API
Filings indexed 536 across all filing types
Latest filing 2010-03-15 Capital/Financing Update
Country US United States of America
Listing US NNVC

About NANOVIRICIDES, INC.

https://www.nanoviricides.com/

NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing a novel class of nanomedicine-based antiviral therapeutics. The company's proprietary platform technology creates "nanoviricides," which are designed to be broad-spectrum drugs that viruses cannot easily evade through mutation. The technology is biomimetic, mimicking the host cell receptors that viruses use for entry. A nanoviricide is engineered to attract and bind to a virus particle, subsequently trapping and dismantling it to neutralize the threat. The company's development pipeline targets a wide range of viral infections, including respiratory viruses such as RSV, influenza, and coronaviruses, as well as herpesviruses (shingles, cold sores), HIV, and hemorrhagic fever viruses.

Recent filings

Filing Released Lang Actions
NANOVIRICIDES INC S-3 A 3-15-2010
Capital/Financing Update Classification · 95% confidence The document is a Form S-3/A Registration Statement filed with the SEC by Nanoviricides, Inc. It is an amendment to a registration statement under the Securities Act of 1933, used for registering securities for public offering. The document includes details about the securities to be offered (common stock, preferred stock, debt securities, warrants), the registration fee, and the prospectus for the offering. It is not a financial report, earnings release, or management discussion, but a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or notice, so it is not a Report Publication Announcement or Regulatory Filing. Confidence is high given the clear identification of the form and content.
2010-03-15 English
Regulatory Filings 2010
Regulatory Filings
2010-03-15 English
NANOVIRICIDES 8-K A 3-9-2010
Board/Management Information Classification · 95% confidence The document is a Form 8-K/A, which is an amendment to a Current Report filed with the SEC. It details the entry into material definitive agreements, specifically employment agreements with executive officers and other key personnel. It also discusses unregistered sales of equity securities related to these agreements. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The content focuses on management agreements and changes in executive employment terms, which aligns with announcements about board or management information. Therefore, the document fits best under the category for Board/Management Information (MANG). The document length (7091 characters) and detailed content about employment agreements support this classification with high confidence.
2010-03-11 English
Regulatory Filings 2010
Regulatory Filings
2010-03-11 English
NANOVIRICIDES 8-K 3-9-2010
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 9, 2010. It reports the entry into material definitive employment agreements with executive officers and other key personnel, detailing terms of employment, compensation, and stock issuance. It also includes information about unregistered sales of equity securities related to these agreements. The document does not contain financial statements or detailed financial performance data but focuses on management agreements and related securities transactions. This type of filing is typically categorized as a current report on significant corporate events, specifically changes in management or executive agreements. Therefore, the most appropriate classification is 'Board/Management Information' (MANG). The document length (6874 characters) and content confirm it is not a brief announcement or a full financial report but a detailed management-related filing.
2010-03-10 English
NANOVIRICIDES, INC S3 3-3-2010
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Nanoviricides, Inc. It is a registration statement under the Securities Act of 1933 for the purpose of registering securities for sale to the public. The document includes a prospectus describing the securities to be offered, the plan of distribution, risk factors, and other related information. This type of filing is related to capital raising and financing activities, specifically the registration of securities for public offering. It is not an annual report, earnings release, or any other type of financial or management report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or a certification, so it is not RPA or RNS. Confidence is high given the clear identification of the form and its purpose.
2010-03-04 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.